Overview Dividends

(RVMD) Revolution Medicines - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US76155X1000

Targeted Therapies, RAS Inhibitors, Cancer Treatments

RVMD EPS (Earnings per Share)

EPS (Earnings per Share) of RVMD over the last years for every Quarter: "2020-09-30": -0.42, "2020-12-31": -0.52, "2021-03-31": -0.53, "2021-06-30": -0.6, "2021-09-30": -0.72, "2021-12-31": -0.71, "2022-03-31": -0.78, "2022-06-30": -0.82, "2022-09-30": -0.87, "2022-12-31": -0.63, "2023-03-31": -0.72, "2023-06-30": -0.92, "2023-09-30": -0.99, "2023-12-31": -1.14, "2024-03-31": -0.7, "2024-06-30": -0.81, "2024-09-30": -0.94, "2024-12-31": -1.12, "2025-03-31": -1.13, "2025-06-30": -1.31,
EPS Growth (3Y CAGR): -47.00%
EPS Trend (3Y Correlation): -67.7%

RVMD Revenue

Revenue of RVMD over the last years for every Quarter: 2020-09-30: 12.661, 2020-12-31: 8.751, 2021-03-31: 10.131, 2021-06-30: 8.698, 2021-09-30: 1.101, 2021-12-31: 9.46, 2022-03-31: 7.578, 2022-06-30: 9.116, 2022-09-30: 3.356, 2022-12-31: 15.33, 2023-03-31: 7.014, 2023-06-30: 3.824, 2023-09-30: 0, 2023-12-31: 0.742, 2024-03-31: 0, 2024-06-30: 0, 2024-09-30: 0, 2024-12-31: 261.592, 2025-03-31: 0, 2025-06-30: 0,
Revenue Growth (3Y CAGR): -80.64%
Revenue Trend (3Y Correlation): -24.2%

Description: RVMD Revolution Medicines

Revolution Medicines Inc (NASDAQ:RVMD) is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The companys pipeline includes RAS(ON) inhibitors and RAS companion inhibitors, which are designed to be used as monotherapy or in combination with other therapeutic agents.

The companys RAS(ON) inhibitors, such as daraxonrasib, elironrasib, and zoldonrasib, are in Phase 1 clinical trials, while its RAS companion inhibitors, including RMC-4630 and RMC-5552, are in Phase 2 and Phase 1 clinical trials, respectively. The companys pipeline is diverse, with multiple candidates targeting different RAS variants, including G12C, G12V, Q61H, and G13C.

From a financial perspective, RVMD has a market capitalization of approximately $7.27 billion, indicating a significant presence in the biotechnology sector. The companys Return on Equity (ROE) is -37.06%, which is expected given its clinical-stage status and ongoing investment in research and development. Key Performance Indicators (KPIs) to monitor include the progress of its clinical trials, particularly the Phase 1 and Phase 2 trials for its lead candidates, as well as its cash burn rate and ability to secure future funding.

In terms of valuation, RVMDs stock price has fluctuated, with a 52-week high of $60.60 and a low of $31.13. The current price is around $37.53, with a 20-day Simple Moving Average (SMA) of $37.79, indicating a relatively stable short-term trend. Investors should monitor the companys progress in its clinical trials, as well as industry trends and competitor activity, to assess the potential for future growth.

RVMD Stock Overview

Market Cap in USD 7,389m
Sub-Industry Biotechnology
IPO / Inception 2020-02-13

RVMD Stock Ratings

Growth Rating 19.1%
Fundamental 20.8%
Dividend Rating -
Return 12m vs S&P 500 -15.5%
Analyst Rating 4.67 of 5

RVMD Dividends

Currently no dividends paid

RVMD Growth Ratios

Growth Correlation 3m 10.2%
Growth Correlation 12m -74.9%
Growth Correlation 5y 27.2%
CAGR 5y 32.15%
CAGR/Max DD 3y 0.66
CAGR/Mean DD 3y 2.15
Sharpe Ratio 12m 0.02
Alpha 0.15
Beta 0.611
Volatility 67.85%
Current Volume 2871.3k
Average Volume 20d 1943.4k
Stop Loss 42.4 (-5.1%)
Signal -1.14

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-812.1m TTM) > 0 and > 6% of Revenue (6% = 15.7m TTM)
FCFTA -0.23 (>2.0%) and ΔFCFTA -3.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 761.5% (prev 204.8k%; Δ -204.0kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.28 (>3.0%) and CFO -684.9m > Net Income -812.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 11.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (188.1m) change vs 12m ago 13.93% (target <= -2.0% for YES)
Gross Margin 94.74% (prev -1324 %; Δ 1418 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 12.35% (prev 0.04%; Δ 12.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -998.3 (EBITDA TTM -883.7m / Interest Expense TTM 899.0k) >= 6 (WARN >= 3)

Altman Z'' -4.51

(A) 0.82 = (Total Current Assets 2.18b - Total Current Liabilities 184.5m) / Total Assets 2.43b
(B) -0.91 = Retained Earnings (Balance) -2.20b / Total Assets 2.43b
(C) -0.42 = EBIT TTM -897.5m / Avg Total Assets 2.12b
(D) -3.90 = Book Value of Equity -2.20b / Total Liabilities 564.2m
Total Rating: -4.51 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 20.78

1. Piotroski 1.0pt = -4.0
2. FCF Yield -10.06% = -5.0
3. FCF Margin data missing
4. Debt/Equity 0.21 = 2.48
5. Debt/Ebitda -0.44 = -2.50
6. ROIC - WACC (= -54.04)% = -12.50
7. RoE -41.78% = -2.50
8. Rev. Trend -24.22% = -1.82
9. EPS Trend -67.68% = -3.38

What is the price of RVMD shares?

As of September 17, 2025, the stock is trading at USD 44.70 with a total of 2,871,283 shares traded.
Over the past week, the price has changed by +9.18%, over one month by +22.63%, over three months by +12.40% and over the past year by +0.36%.

Is Revolution Medicines a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Revolution Medicines (NASDAQ:RVMD) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 20.78 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RVMD is around 44.76 USD . This means that RVMD is currently overvalued and has a potential downside of 0.13%.

Is RVMD a buy, sell or hold?

Revolution Medicines has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RVMD.
  • Strong Buy: 8
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the RVMD price?

Issuer Target Up/Down from current
Wallstreet Target Price 72.4 62%
Analysts Target Price 72.4 62%
ValueRay Target Price 49.6 10.9%

Last update: 2025-09-04 04:47

RVMD Fundamental Data Overview

Market Cap USD = 7.39b (7.39b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 2.14b USD (Cash And Short Term Investments, last quarter)
P/S = 9035.0954
P/B = 3.8051
Beta = 1.159
Revenue TTM = 261.6m USD
EBIT TTM = -897.5m USD
EBITDA TTM = -883.7m USD
Long Term Debt = 379.7m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 13.1m USD (from shortTermDebt, last quarter)
Debt = 392.8m USD (Calculated: Short Term 13.1m + Long Term 379.7m)
Net Debt = -269.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.65b USD (7.39b + Debt 392.8m - CCE 2.14b)
Interest Coverage Ratio = -998.3 (Ebit TTM -897.5m / Interest Expense TTM 899.0k)
FCF Yield = -10.06% (FCF TTM -567.7m / Enterprise Value 5.65b)
FCF Margin = -217.0% (FCF TTM -567.7m / Revenue TTM 261.6m)
Net Margin = -310.4% (Net Income TTM -812.1m / Revenue TTM 261.6m)
Gross Margin = 94.74% ((Revenue TTM 261.6m - Cost of Revenue TTM 13.8m) / Revenue TTM)
Tobins Q-Ratio = -2.57 (set to none) (Enterprise Value 5.65b / Book Value Of Equity -2.20b)
Interest Expense / Debt = 0.23% (Interest Expense 899.0k / Debt 392.8m)
Taxrate = 21.0% (US default)
NOPAT = -897.5m (EBIT -897.5m, no tax applied on loss)
Current Ratio = 11.79 (Total Current Assets 2.18b / Total Current Liabilities 184.5m)
Debt / Equity = 0.21 (Debt 392.8m / last Quarter total Stockholder Equity 1.87b)
Debt / EBITDA = -0.44 (Net Debt -269.7m / EBITDA -883.7m)
Debt / FCF = -0.69 (Debt 392.8m / FCF TTM -567.7m)
Total Stockholder Equity = 1.94b (last 4 quarters mean)
RoA = -33.42% (Net Income -812.1m, Total Assets 2.43b )
RoE = -41.78% (Net Income TTM -812.1m / Total Stockholder Equity 1.94b)
RoCE = -38.63% (Ebit -897.5m / (Equity 1.94b + L.T.Debt 379.7m))
RoIC = -46.17% (NOPAT -897.5m / Invested Capital 1.94b)
WACC = 7.86% (E(7.39b)/V(7.78b) * Re(8.27%)) + (D(392.8m)/V(7.78b) * Rd(0.23%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 7.53%
Discount Rate = 8.27% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -567.7m)
EPS Correlation: -67.68 | EPS CAGR: -47.00% | SUE: -1.30 | # QB: 0
Revenue Correlation: -24.22 | Revenue CAGR: -80.64%

Additional Sources for RVMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle